You are here

Human Clinical Trials Initiated for Topotecan Using Transmembrane Carrier System

VANCOUVER, April 16 /PRNewswire-FirstCall/ -- Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) announced today that GlaxoSmithKline ("GSK"; LSE and NYSE: GSK) has filed an Investigational New Drug application (IND) with the United States Food and Drug Administration (FDA) asking for approval to begin human clinical trials evaluating GSK's anticancer drug topotecan encapsulated in INEX's proprietary drug delivery technology, known as Transmembrane Carrier System (TCS).

David Main, President and CEO of INEX, said INEX earned US$1.5 million in the first quarter of 2003 in milestone payments to support the filing of the IND and the ongoing development of the product. Since the two companies entered their partnership in late 2001, GSK has paid INEX a total of US$4.5 million in upfront and milestone payments.

INEX will qualify for additional milestone payments as GSK's drug moves through clinical development and commercialization. GSK is responsible for all development costs and INEX will receive a royalty on the drug's sales upon commercialization.

Encapsulating anticancer drugs inside INEX's proprietary TCS drug delivery technology may provide prolonged blood circulation, accumulation in tumors and extended drug release of the encapsulated drug at the cancer site.

Topotecan is the second chemotherapeutic agent to be encapsulated using INEX's TCS technology. The company's lead product, Onco TCS, is the encapsulation of the anticancer drug vincristine. INEX plans to file in the third of quarter of 2003 a New Drug Application for Onco TCS as a treatment for relapsed aggressive non-Hodgkin's lymphoma. Onco TCS is also being evaluated in several phase II clinical trials in combination and stand-alone therapy for several other cancers.

INEX is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer.

Statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "may," "plans," "will," "estimate," "continue," "anticipates," "intends," "expects," and similar expressions, constitute "forward-looking statements". Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.

INEX investor contact: INEX media contact: Ian Mortimer Maria Loscerbo Director, Investor Relations James Hoggan & Associates Inc. Inex Pharmaceuticals Corp. Tel: 604-739-7500 Tel: 604-419-3200 Email: mloscerbo@hoggan.com Email: info@inexpharm.com Website: www.inexpharm.com

INEX's common shares are traded on the Toronto Stock Exchange under the trading symbol "IEX".

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks